K
Kevin H. Liu
Researcher at Walter and Eliza Hall Institute of Medical Research
Publications - 13
Citations - 868
Kevin H. Liu is an academic researcher from Walter and Eliza Hall Institute of Medical Research. The author has contributed to research in topics: Cell growth & Cancer. The author has an hindex of 11, co-authored 13 publications receiving 650 citations. Previous affiliations of Kevin H. Liu include University of Melbourne.
Papers
More filters
Journal ArticleDOI
Construction of developmental lineage relationships in the mouse mammary gland by single-cell RNA profiling.
Bhupinder Pal,Bhupinder Pal,Yunshun Chen,Yunshun Chen,François Vaillant,François Vaillant,Paul R. Jamieson,Lavinia Gordon,Anne C. Rios,Anne C. Rios,Stephen Wilcox,Nai Yang Fu,Nai Yang Fu,Kevin H. Liu,Felicity C. Jackling,Melissa J. Davis,Melissa J. Davis,Geoffrey J. Lindeman,Geoffrey J. Lindeman,Geoffrey J. Lindeman,Gordon K. Smyth,Gordon K. Smyth,Jane E. Visvader,Jane E. Visvader +23 more
TL;DR: Findings point to a developmental hierarchy in which a basal-like gene expression program prevails in the early post-natal gland prior to the specification of distinct lineage signatures, and the presence of cellular intermediates that may serve as transit or lineage-primed cells.
Journal ArticleDOI
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Delphine Merino,Delphine Merino,James R. Whittle,James R. Whittle,James R. Whittle,François Vaillant,François Vaillant,Antonin Serrano,Antonin Serrano,Jia-Nan Gong,Jia-Nan Gong,Göknur Giner,Göknur Giner,Ana Leticia Maragno,Maïa Chanrion,Emilie Schneider,Bhupinder Pal,Bhupinder Pal,Xiang Li,Xiang Li,Grant Dewson,Grant Dewson,Julius Gräsel,Julius Gräsel,Kevin H. Liu,Kevin H. Liu,Najoua Lalaoui,Najoua Lalaoui,David J. Segal,David J. Segal,Marco J Herold,Marco J Herold,David C.S. Huang,David C.S. Huang,Gordon K. Smyth,Gordon K. Smyth,Olivier Geneste,Guillaume Lessene,Guillaume Lessene,Jane E. Visvader,Jane E. Visvader,Geoffrey J. Lindeman +41 more
TL;DR: The MCL-1 inhibitor S63845 is effective in combination with conventional therapy for targeting triple-negative and HER2-amplified breast cancer and a protein that can promote treatment resistance is identified, which may help predict which patients are more likely to benefit from the new treatment.
Journal ArticleDOI
Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive
Nai Yang Fu,Anne C. Rios,Anne C. Rios,Bhupinder Pal,Bhupinder Pal,Charity W. Law,Charity W. Law,Paul R. Jamieson,Ruijie Liu,François Vaillant,François Vaillant,Felicity C. Jackling,Kevin H. Liu,Gordon K. Smyth,Gordon K. Smyth,Geoffrey J. Lindeman,Geoffrey J. Lindeman,Geoffrey J. Lindeman,Matthew E. Ritchie,Matthew E. Ritchie,Jane E. Visvader,Jane E. Visvader +21 more
TL;DR: Interestingly, the deeply quiescent MaSC subset (Lgr5+Tspan8hi) resides within the proximal region throughout life, and has a transcriptome strikingly similar to that of claudin-low tumours.
Journal ArticleDOI
P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways
TL;DR: It is concluded that PAK1 stimulates colon cancer cell proliferation, migration/invasion, and survival via ERK- and AKT-dependent pathways and the PAK 1 convergence point could be an alternative target for CRC therapy.
Journal ArticleDOI
Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer.
Delphine Merino,Tom S. Weber,Tom S. Weber,Antonin Serrano,Antonin Serrano,François Vaillant,François Vaillant,Kevin H. Liu,Kevin H. Liu,Bhupinder Pal,Bhupinder Pal,L Di Stefano,Jaring Schreuder,Jaring Schreuder,Dawn S. Lin,Dawn S. Lin,Yunshun Chen,Yunshun Chen,Marie Liesse Asselin-Labat,Marie Liesse Asselin-Labat,Ton N. Schumacher,Daniel L Cameron,Gordon K. Smyth,Gordon K. Smyth,Anthony T. Papenfuss,Geoffrey J. Lindeman,Jane E. Visvader,Jane E. Visvader,Shalin H. Naik,Shalin H. Naik +29 more
TL;DR: In this article, cellular barcoding of two treatment-naive TNBC patient-derived xenografts (PDXs) was used to track the spatio-temporal fate of thousands of barcoded clones in primary tumors, and their metastases.